Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Accendra Health Reports Narrowed $19.7M Net Loss as Q3 Revenue Declines to $601.8M

Accendra Health reported a significantly narrowed net loss for the third quarter of 2026, though revenue and pretax income faced downward pressure. The company is currently executing a divestiture strategy and working to regain NYSE listing compliance following a period of substantial market capitalization decline.

Cranes, industry, crane system, port. Stock photo illustrating Accendra Health's financial results story.
ACCENDRA HEALTH INC/VA/ · Photo: wal_172619 / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 601.77697.26
Pretax Income -36.82-3.63
Net Income -19.70-150.28
Diluted EPS -0.25-1.94
Net Income YoY
+86.9%

Key highlights

  • Net loss improved by 86.9% year-over-year to $19.70 million compared to $150.28 million in Q3 2025
  • Total net revenue declined to $601.77 million from $697.26 million in the prior year period
  • Pretax loss widened to $36.82 million from a $3.63 million loss a year ago
  • Full-year 2026 revenue guidance was lowered to the bottom of the $2,450 million to $2,550 million range
  • A second non-core asset sale part of a $45 million transaction is expected to close by year-end 2026

How the Period Went

Accendra Health experienced a sharp revenue contraction during the third quarter of 2026, with sales falling to $601.77 million from $697.26 million in the same period last year. Despite the lower top-line performance, the company significantly narrowed its net loss to $19.70 million, an 86.9% improvement over the $150.28 million loss reported in the third quarter of 2025. This resulted in a diluted loss per share of $0.25, compared to $1.94 a year ago. However, the operational picture remained pressured as pretax income fell to a loss of $36.82 million, a steep decline from the $3.63 million pretax loss in the prior year.

Margins and Profitability

The company’s profitability profile is heavily influenced by its ongoing restructuring and high accumulated deficit, which reached $568.2 million as of September 30, 2026. Management updated its full-year guidance on November 5, 2026, via Business Wire, indicating that adjusted EBITDA for 2026 is expected to be approximately $217 million. This figure is roughly 30% lower than previous midpoints, reflecting the impact of declining revenues. To stabilize the balance sheet, Accendra is divesting non-core assets. An SEC filing from August confirmed that the sale of a second asset, contributing to a total transaction value of approximately $45 million, is scheduled for completion by December 31, 2026.

Business Overview

Accendra Health operates in the medical distribution industry, serving as a critical link in the healthcare supply chain. The company provides logistics and distribution services for medical supplies to various end markets, including hospitals and clinical facilities across the United States. In the face of recent financial challenges, the company has pivoted toward a leaner operating model by offloading secondary assets. This strategic refocusing is intended to address the company's current micro-cap valuation of approximately $22.9 million and its recent stock price volatility, which has seen the share price trade below $0.30.

ACCENDRA HEALTH INC/VA/ share price · last month
Line chart of ACCENDRA HEALTH INC/VA/'s share price over the last month, from $0.22 on 19 Oct → $0.09 on 16 Nov; our story on 6 Nov at $0.30.

Down 71.3% since our story on 6 Nov: $0.30 when we broke it → $0.09 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$0.22
20 Oct$0.26
21 Oct$0.22
22 Oct$0.21
23 Oct$0.22
26 Oct$0.20
27 Oct$0.20
28 Oct$0.23
29 Oct$0.23
30 Oct$0.25
2 Nov$0.26
3 Nov$0.28
4 Nov$0.28
5 Nov$0.30
6 Nov$0.20
9 Nov$0.18
10 Nov$0.15
11 Nov$0.15
12 Nov$0.15
13 Nov$0.13
16 Nov$0.09

Financial Context and Compliance

The third quarter results follow a period of intense market pressure, with Accendra's stock price dropping 89.8% over the last quarter. According to reports from Business Wire, the company received a notice of non-compliance from the NYSE on October 27, 2026, regarding Section 802.01B. Accendra must submit a business plan by December 11, 2026, detailing its strategy to regain listing compliance within an 18-month window. With a Relative Strength Index (RSI) of 35.6, technical indicators suggest the stock is nearing oversold levels, while the company maintains an annual revenue base of $2,762.03 million despite its shrinking market capitalization.

Industry Landscape

  • Medical distribution providers are facing increased pressure to optimize logistics as supply chain costs remain elevated.
  • Smaller healthcare distributors are increasingly turning to divestitures of non-core assets to maintain liquidity.
  • Consolidation among healthcare providers has shifted bargaining power, impacting the margins of independent distributors.
  • Market sentiment for micro-cap healthcare stocks remains cautious amid high interest rates and regulatory scrutiny.
  • Peer comparisons show a widening gap between large-scale national distributors and specialized regional players.
ACCENDRA HEALTH INC/VA/ · financial snapshot
Share price$0.30
Market cap$23M
Revenue (annual)$2.8B
1-month price change-36.17%
SectorHealthcareMedical Distribution

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Accendra Health Inc/VA/ announcing its third quarter 2026 financial results.

Read the filing ↗

Track ACCENDRA HEALTH INC/VA/ live

Get the next ACCENDRA HEALTH INC/VA/ SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.